Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?

Yİ?İTTÜRK, Duygu; Kaya, Burhanettin; Unal, Suheyla

Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?

Duygu Yİ?İTTÜRK, (Uzm. Dr., Eski?ehir Devlet Hastanesi, Psikiyatri, Eski?ehir)

Burhanettin KAYA, (Doç. Dr., Özel Terapi T?p Merkezi, Antalya)

Süheyla ÜNAL (3Prof. Dr., ?nönü Üniversitesi T?p Fakültesi Psikiyatri AD, Malatya)

Klinik Psikiyatri Dergisi

10 4

Yıl: 2017 Cilt: 20 Sayı: 1 Sayfa Aralığı: 19 - 29 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?

Öz:

Amaç: Bu çal??mada ?izofreni hastalar?nda psikotik belirtilerin alevlenme döneminde dikkat ve bellek i?levlerdegözlenen bozulman?n, belirtilerdeki gerilemeye paralelolarak düzelme gösterece?i hipotezi test edilmi?tir.Gereç ve Yöntem:Ara?t?rman?n verileri Kas?m 2003-Ocak2005 tarihleri aras?nda ?nönü Üniversitesi T?p FakültesiTurgut Özal T?p Merkezinde toplanm??t?r. Psikiyatri servisve poliklini?inde ayaktan ve/veya yatarak takip ve tedaviedilmekte olan, DSM-IV tan? ölçütlerine göre ?izofrenibozuklu?u tan?s? alan ve tümü antipsikotik ilaç kullanmakta olan, 18-50 ya?lar? aras?nda 27 hasta çal??mayaal?nm??t?r. Hastalara belirtilerin alevli oldu?u dönemdeK?sa Psikiyatrik De?erlendirme Ölçe?i (BPRS), PozitifSemptomlar? De?erlendirme Ölçe?i (SAPS), NegatifSemptomlar? De?erlendirme Ölçe?i (SANS), Yan EtkiDerecelendirme Ölçe?i (UKU) uygulanm??, ayn? günWechsler Bellek Ölçe?i (WMS-R), Stroop testi ve SözelBellek Süreçleri Testi (SBST) yap?lm??t?r. Ayn? uygulamahastalar?n belirtileri belirgin derecede geriledi?inde(BPRS puanlar?nda en az %50 azalma oldu?unda) tekrarlanm??t?r. ?ki dönemde uygulanan testler WilcoxonSigned Ranks Test ile kar??la?t?r?lm??t?r. Bulgular:Hastal???n belirtilerinin yat??t??? dönemde WMS-Rtestinde ki?isel aktüel bilgi, yönelim, konsantrasyon,mant?ksal bellek ve dikkat puanlar? ile SBST de uzun vek?sa süreli bellek puanlar? alevli dönemdekine göreanlaml? düzeyde daha yüksek; tüm Stroop alt test puanlar? daha dü?ük bulunmu?tur. Sonuç: ?izofreni bozuklu?unda belirtilerin artt??? dönemde gözlenen dikkat vebellek i?levlerindeki bozulma, belirtilerin yat??mas? ilegeriye dönebilmektedir. Bu gözlem ?izofreni hastalar?ndaki bili?sel y?k?m?n azalmas? aç?s?ndan alevlenmelerinönlenmesinin önemini ortaya koymaktad?r

Anahtar Kelime:

Konular: Psikiyatri

Reflection of Symptomatic Improvement in Attention and Memory Functions in Patients with Schizophrenia

Öz:

Objective: In this study, we proposed that if schizophrenic symptoms will decrease with drug treatment, itwould be improvement in attention and memory functions. Method: This research has been done in InonuUniversity Turgut Ozal Medicine Center Psychiatry Clinicbetween 2003- 2005. We included 27 patients whoseages ranged between 18-50 and who were inpatientsand/or outpatients of Psychiatry Clinic, treated with thediagnosis of schizophrenia according to DSM-IV diagnosis criteria. During their acute periods Brief PsychiatricRating Scale (BPRS), Positive Symptoms Rating Scale(SAPS), Negative Symptoms Rating Scale (SANS) andUKU Side Affect Assessment Inquiry were applied topatients and, at the same day they were also givenWechsler Memory Scale (WMS-R), Stroop Test and aVerbal Test of Memory Process (SBST). Same procedureswere repeated when their symptoms improvement(when their BPRS scores were reduced at least %50). Byusing Wilcoxon Signed Ranks Test, we compared psychometric measures that were performed in patients in twoperiods. Results: When the results of neuropsychologicaltests in the acute and symptom resolution periods werecompared, in WMS-R test; personal and current information task, orientation, concentration, logical memoryand attention scores, in SBST; long and short periodmemory scores were found significantly higher, and allStroop subtest scores were found significantly lower inthe response to treatment. Conclusion: In our study, wefound that schizophrenia patients have better attentionand memory functions when positive and negativesymptoms were regressed. This observation supports theimportance of prevention of exacerbations in terms ofreduction cognitive deteriorations in patients with schi zophrenia.

Anahtar Kelime:

Konular: Psikiyatri

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Phillips ML, David AS. Cognitive impairments as causes of positive symptoms in schizophrenia. SharmaT, Harvey P (editörler) Cognition in Schizophrenia: Impairments, Importance and Treatment Strategies. Oxford: Oxford University Press, 2000, pp. 210-228.
2. Manglam MK, Ram D, Praharaj SK, Sarkhel S. Working memory in schizophrenia. German J Psychiatry 2010; 13: 116- 120.
3. Byer LE. The Longitudinal Relationships between Symptoms and Cognition in Schizophrenia. Honors Theses. Wesleyan University. 2012.
4. Morris R, Griffiths O, Le Pelley ME, Weickert TW. Attention to irrelevant cues is related to positive symptoms in schizophrenia. Schizophr Bull 2013; 39:575-82.
5. Chang WC, Ming Hui CL, Yan Wong GH, Wa Chan E, Ming Lee EH, Hai Chen EY. Symptomatic remission and cognitive impairment in first episode schizophrenia: A prospective 3 year follow-up study. J Clin Psychiatry 2013; 74: e1046-e1053.
6. Lett TA, Voineskos AN, Kennedy JL, Levine B, Daskalakis ZJ. Treating working memory deficits in schizophrenia: A review of the neurobiology. Biol Psychiatry 2014; 71: 361-370.
7. Zhao J, Zhang Y, Chao YY, Ma J, Yang YF, Zhao JY, Du YH, Li WW, Song XQ, Lü LX. Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia. Zhonghua Yi Xue Za Zhi. 2016;11;96: 2960-2964.
8. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51:124-131.
9. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003; 26:25-40.
10. Knowles EEM, Weiser M, David AS ve ark. The puzzle of processing speed, memory, and executive function ?mpairments in schizophrenia: Fitting the pieces together. Biol Psychiatry 2015; 78:786-793.
11. Javitt DC, Liederman E, Cienfuegos A ve ark. Panmodal Processing Imprecision as a Basis for Dysfunction of Transient Memory Storage Systems in Schizophrenia. Schizophr Bull 1999; 25: 763-775.
12. Morris R, Griffiths O, Le Pelley ME, Weickert TW. Attention to irrelevant cues is related to positive symptoms in schizophrenia. Schizophr Bull 2013; 39:575-82.
13. Bruder GE, Wexler BE, Sage MM ve ark. Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits. Schizophr Res 2004; 68:137-147.
14. Leiderman EA, Strejileyich SA. Visuospatial deficits in schizophrenia: central executive and memory subsystems impairments. Schizophr Res 2004; 68:217-223.
15. Barch DM. The cognitive neuroscience of schizophrenia. Cannon T, Mineka S (editörler). Ann Rev Clin Psychology. Washington, DC: American Psychological Association, 2005, pp. 321-353.
16. Hashimoto R, Lee KU, Preus A, McCarley RW, Wible CG. An fMRI study of functional abnormalities in the verbal working memory system and the relationship to clinical symptoms in chronic schizophrenia. Cerebr Cortex 2010; 20:46-60.
17. Keefe RSE Working memory dysfunction and its relevance to schizophrenia. Cognition in schizophrenia içinde. T Sharma, P Harvey (editörler) Oxford University Press, 2000, pp. 16-50.
18. Baddeley AD, Hitch G. Working memory. GH Bower editör, The psychology of learning and motivation: Advances in research and theory içinde. New York: Academic Press, 1974, pp. 47-89.
19. Glahn DC, Therman S, Manninen M ve ark. Spatial working memory as an endophenotype for schizophrenia. Biol Psychiatry 2003; 53:624-626.
20. Lee J, Park S. Working memory impairments in schizophrenia: a meta-analysis. J Abnorm Psychol 2005;114:599-611.
21. Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms Trends Cogn Sci 2012; 16:27- 34.
22. Park S, Gooding DC. Working memory impairment as an endophenotypic marker of a schizophrenia diathesis. Schizophr Res: Cognit 2014; 1:127-136.
23. Ünal S. ?izofrenide bili?sel i?lev bozukluklar? ve belirti olu?umu ile ili?kisi. Anadolu Psik Derg, 2003; 4:46-53.
24. Hoff AL, Svetina C, Shields G, Stewart J, DeLisi E. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr Res 2005; 78:27-34.
25. Albus M, Hubmann W, Mohr F, Hech, S, HinterbergerWeber P, Seitz NN, Küchenhoff H. Neurocognitive functioning in patients with first- episode schizophrenia: Results of a prospective 5-year follow-up study. Eur Arch Psychiatry Clin Neurosci 2006; 256;7:442-451.
26. Bell MD, Mishara AL. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments. Schizoph Res 2006; 81: 17 - 21.
27. Verma SS, Abdin ME, Poon LY, Chong SA. Symptomatic and functional remission in patients with first-episode psychosis. Acta Psychiatr. Scand 2012; 126:282-289.
28. Franza F, Carpentieri G, De Guglielmo S, Fasano V, Fiorentino N, Perito M, Solomita B, Del Buono G. Neurocognitive management of the primary negative symptoms of schizophrenia: a role of atypical antipsychotics. Psychiatr Danub 2016; 28(Suppl-1):145-148.
29. Özcan Y, Öz???k HI, Ünal S, Özcan M. Risperidonun ?izofreninin pozitif ve negatif belirtileri ve bellek i?levi üzerine etkisi. Bull of Clin Psychopharmacol 2000;10: 182-188.
30. Lee J, Park S. Effects of Antipsychotic Drugs on Memory and Attention in Schizophrenia. Psychiatry Invest 2006; 3 (1):55- 65.
31. Keefe RS, Bilder RM, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007; 64:633-47.
32. Davidson M, Galderisi S, Weiser M Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, RiecherRössler A, Kahn RS. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009; 166: 675-82.
33. Hofer A, Bodner T, Kaufmann A Kemmler G, Mattarei U, Pfaffenberger NM, Rettenbacher MA, Trebo E, Yalcin N, Fleischhacker WW. Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychol Med 2011; 22:1-9.
34. Amerikan Psikiyatri Birli?i. Mental Bozukluklar?n Tan?sal ve Say?msal El Kitab?. E.Köro?lu çeviri editörü. Hekimler Yay?n Birli?i, Ankara, 1994.
35. Wechsler DA. WMS-R: Wechsler Memory Scale-Revised (the Psychological Corporation). Harcourt, Brace, Jovanovich, New York, 1987.
36. Karaka? S, Eski R, Ba?er E. Türk kültürü için standardizasyonu yap?lm?? bir nöropsikolojik testler toplulu?u: B?LNOT Bataryas?. 32. Ulusal Nöroloji Kongresi Kitab?, Ufuk Matbaas?, ?stanbul, 1996.
37. Stroop JR. Studies of interference in serial verbal reaction. J Exp Psychology 1935; 18: 643-662.
38. Öktem Ö. Sözel Süreçleri Testi (SBST). Bir Ön Çal??ma. Nöropsikiyatri Ar?ivi 1992; 29:196-206.
39. Andreasen NC, Olsen S. Negative-positive schizophrenia: definition and validation. Arch Gen Psychiayty 1982; 39: 789- 794.
40. Erkoç ?, Arkonaç O, Atakl? C, Özmen E. Pozitif belirtileri de?erlendirme ölçe?inin güvenilirli?i ve geçerlili?i. Dü?ünen Adam 1991; 2: 20-24.
41. Andreasen NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982; 39: 784-788.
42. Erkoç ?, Arkonaç O, Atakl? C, Özmen E. Negatif belirtileri de?erlendirme ölçe?inin güvenilirli?i ve geçerlili?i. Dü?ünen Adam 1991; 2: 16-18.
43. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Reports 1962; 10: 799-812.
44. Soykan Ç. Institutional differences and case typicality as related to diagnosis symptom severity, prognosis and treatment. Yay?nlanm?? master tezi. Orta Do?u Teknik Üniversitesi, 1990.
45. Lingjaerde O, Ahlfors UG, Bech P Dencker SJ, Elgen K. The UKU Side Effect Rating Scale. Acta Psychiatr Scand 1987; 76 (suppl 334): 1-96.
46. Hoff AL, Sakuma M, Wieneke M Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 1999;156: 1336-1341.
47. Akdede K?v?rc?k BB, Alptekin K, Kiti? A Arkar H, Akvardar Y. Effects of quetiapine on cognitive functions in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:233- 238.
48. Miles AA, Heinrich RW, Ammari N, Hartman L, McDermid Vaz S, Muharib E. Stability and change in symptoms, cognition, and community outcome in schizophrenia. Schizophr Res 2014; 152; 435-439.
49. Lyketsos CG, Chen L, Antony JC. Cognitive decline in adulthood: An 11.5 year follow-up of the Baltimore Epidemiologic Catchment Area Study. Am J Psychiatry 1999;156: 58-65.
50. Moore DJ, Palmer BW, Jeste DV. Use of the mini-mental state exam in middle-aged and older outpatients with schizophrenia: cognitive impairment and its associations. Am J Geriatr Psychiatry 2004; 12:412-419.
51. Moustafa AA, Garami JK, Mahlberg J, Golembieski J, Keri S, Misiak B, Frydecka D. Cognitive function in schizophrenia: conflicting findings and future directions. Rev Neurosci. 2016;1;27:435-48.
52. Houthoofd SAMK, Morrens, M, Sabbe BCC. Cognitive and Psychomotor Effects of Risperidone in Schizophrenia and Schizoaffective Disorder. Clinical Therapeutics 2008; 30:1565- 1589.
53. Orman K. ?izofreni hastalar?nda elektrokonvulsif tedavinin baz? dikkat testleri üzerine etkileri. Uzmanl?k tezi. ?nönü Üniversitesi, Malatya, 2016.
54. Landro NI. Memory function in schizophrenia. Acta Psychiatr Scand 1994; 90 (384 Suppl):87S-94S.
55. Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007;164:1585-92.
56. Braff DL. Reply to cognitive therapy and schizophrenia. Schizoph Bull 1992; 18:37-38.
57. Meltzer HY, Mc Gurk SR. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233-255.
58. Hori H, Noguchi H, Hashimoto R Nakabayashi T, Omori M, Takahashi S, Tsukue R, Anami K, Hirabayashi N, Harada S, Saitoh O, Iwase M, Kajimoto O, Takeda M, Okabe S, Kunugi H. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006; 86 (1-3):138-146.
59. Akdede BB, Alptekin K. ?izofrenide bili?sel i?lev bozukluklar? ve antipsikotik tedavi. Bull of Clin Psychopharmacol 2004; 14: 178-184.
60. Krausz M, Moritz SH, Naber D, Lambert M, Andresen B. Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction. Eur Psychiatry 1999; 14: 84-88.
61. Gallhofer B, Lis S, Meyer-Lindenberg A, Krieger S. Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Acta Psychiatr Scand Suppl 1999; 395: 118-128.
62. Liemburg EJ, Knegtering H, Klein, HC, Kortekaas R, Aleman A. Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings. Eur Neuropsychopharm 2012; 22: 387-400.
63. Kayahan B, Veznedaro?lu B, Öztürk Ö, Ersoy MA.Atipik antipsikotik ilaçlar?n ?izofreni hastalar?nda k?sa kognitif muayene (KKM) üzerine etkisi: Tipik antipsikotiklerle kar??la?t?rmal? - do?al izlem çal??mas?. Anadolu Psik Derg 2004; 5:206-21.
64. Keefe RSE, Young CA, Rock SL, Purdon SE, Gold JM, Breier A; HGGN Study Group. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr 2006; 81:1-15.
65. Crespo-Facorro B, Rodríguez-Sánchez JM, Pérez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, Martínez-Garcia O, Vázquez-Barquero JL. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry. 2009; 21;70:717-29.
66. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154:799-804.
67. Ç?tak S, Çak?c? ET, Çak?c? M. Haloperidol veya klozapin ile tedavi edilmekte olan ?izofrenik hastalarda nöropsikolojik de?erlendirme. Bull of Clin Psychopharmacol 2009; 19:5-14.
68. McGurk SR, Powchik P. The central cholinergic system and cognitive dysfunction in schizophrenia. Cognition in Schizophrenia, T Sharma, P Harvey (editörler), Oxford University Press, 2000, pp. 266-285.
69. Heaton R. Pulsen Heaton R, Paulsen J, Kuck J, Zisook S, Braff D, Harris J, Jeste DV. Neuropsychological deficits in schizophrenia: relationship to age, chronicity and dementia. Arch Gen Psychiatry 1994; 51:469-476.
70. Aksaray G, Oflu S, Kaptano?lu C, Seber G. ?izofrenide bili?sel i?levlerin klinik özellikler ve klinik alt tiplerle ili?kisi. 3P Dergisi 2000; 8: 198-205.
71. Gold S, Arndt S, Nopoulos P, O'Leary DS, Andreasen NC. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 1999;156:1342- 1348.
72. Tracy JI, Monaca C, Giovannetti T, Abraham G, Josiassen RC. Anticholinergicity and cognitive processing in chronic schizophrenia. Biol Psychology 2001; 56: 1-22.
73. Sandyk R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci 1993; 70: 193-197.
74. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002; 27: 479-97.
75. Poorthuis RB, Mansvelder HD. Nicotinic acetylcholine receptors controlling attention: Behavior, circuits and sensitivity to disruption by nicotine. Biochem Pharmacology 2013; 86: 1089-1098.
76. Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy. Schizophr Res 2013; 148:138-144.
77. Y?ld?z M, Kutlu H, Tural Ü. ?izofrenide bili?sel i?levler nüfus ve klinik özelliklerden etkilenir mi? Bull of Clin Psychopharmacol 2011; 21:131-8.
78. Townsend LA, Norman RM, Malla AK, Rychlo AD, Ahmed RR. Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders. Psychiatr Res 2002; 113: 69-81.
79. Alptekin K, Akvardar Y, Akdede K?v?rc?k BB, Dumlu K, I?ik D, Pirinçci F, Yahssin S, Kiti? A. Is quality of life associated with cognitive impairment in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:239- 244.
80. El- Missiry A, Elbatrawy A, El Missiry M, Moneim DA, Ali R, Essawy H. Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia. J Psychiatr Res 2015; 70:106-12.
81. Matza LS, Buchanan R, Purdon S, Brewster-Jordan J, Zhao Y, Revicki DA. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr Bull 2006; 32:666-678.
82. Bowie CR, McGurk SR, Mausbach B, Patterson TL, Harvey PD. Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior. Am J Psychiatry 2012; 169: 710- 718.
83. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol 2012; 213:11-37.
84. Hori H, Yoshimura R, Katsuki A, Atake K, Nakamura J. Current Pharmacotherapy Strategies and Considerations for the Cognitive Dysfunction Associated with Schizophrenia: A Mini Review. Int J Neurol Neurother 2015; 2:1-3.

APA	Yİ?İTTÜRK D, Kaya B, Unal S (2017). Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. , 19 - 29.
Chicago	Yİ?İTTÜRK Duygu,Kaya Burhanettin,Unal Suheyla Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. (2017): 19 - 29.
MLA	Yİ?İTTÜRK Duygu,Kaya Burhanettin,Unal Suheyla Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. , 2017, ss.19 - 29.
AMA	Yİ?İTTÜRK D,Kaya B,Unal S Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. . 2017; 19 - 29.
Vancouver	Yİ?İTTÜRK D,Kaya B,Unal S Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. . 2017; 19 - 29.
IEEE	Yİ?İTTÜRK D,Kaya B,Unal S "Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?." , ss.19 - 29, 2017.
ISNAD	Yİ?İTTÜRK, Duygu vd. "Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?". (2017), 19-29.

APA	Yİ?İTTÜRK D, Kaya B, Unal S (2017). Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. Klinik Psikiyatri Dergisi, 20(1), 19 - 29.
Chicago	Yİ?İTTÜRK Duygu,Kaya Burhanettin,Unal Suheyla Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. Klinik Psikiyatri Dergisi 20, no.1 (2017): 19 - 29.
MLA	Yİ?İTTÜRK Duygu,Kaya Burhanettin,Unal Suheyla Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. Klinik Psikiyatri Dergisi, vol.20, no.1, 2017, ss.19 - 29.
AMA	Yİ?İTTÜRK D,Kaya B,Unal S Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. Klinik Psikiyatri Dergisi. 2017; 20(1): 19 - 29.
Vancouver	Yİ?İTTÜRK D,Kaya B,Unal S Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?. Klinik Psikiyatri Dergisi. 2017; 20(1): 19 - 29.
IEEE	Yİ?İTTÜRK D,Kaya B,Unal S "Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?." Klinik Psikiyatri Dergisi, 20, ss.19 - 29, 2017.
ISNAD	Yİ?İTTÜRK, Duygu vd. "Şizofreni Hastalar?nda Psikotik Belirtilerdeki Düzelmenin Dikkat ve Bellek ??levleri Üzerine Yans?mas?". Klinik Psikiyatri Dergisi 20/1 (2017), 19-29.